Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Haynes

Showing results (151-160 of 164) with videos related to

Pageof 17
Sort By:
Clinical Trials (London, England)|November 18, 2018
FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trialNoelle M Cocoros, Sean D Pokorney, Kevin Haynes, et al.
Journal of Clinical Epidemiology|October 1, 2020
PCORnet® 2020: current state, accomplishments, and future directionsChristopher B Forrest, Kathleen M McTigue, Adrian F Hernandez, et al.
Pharmacoepidemiology and Drug Safety|September 16, 2011
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systemsLisa J Herrinton, Jeffrey R Curtis, Lang Chen, et al.
The American Journal of Gastroenterology|December 12, 2022
Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's DiseaseMichael D Kappelman, Sruthi Adimadhyam, Laura Hou, et al.
Pharmacoepidemiology and Drug Safety|June 5, 2021
Validation of an ICD-10-based algorithm to identify stillbirth in the Sentinel SystemSusan E Andrade, Mayura Shinde, Tiffany A Moore Simas, et al.
BMJ Open Diabetes Research & Care|September 8, 2017
Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomesVincent Lo Re, Dena M Carbonari, M Elle Saine, et al.
JAMIA Open|November 29, 2023
Evaluating the impact of alternative phenotype definitions on incidence rates across a global data networkRupa Makadia, Azza Shoaibi, Gowtham A Rao, et al.
Pharmacoepidemiology and Drug Safety|July 6, 2012
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studiesVincent Lo Re, Kevin Haynes, Eileen E Ming, et al.
Pharmacoepidemiology and Drug Safety|January 11, 2018
Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel SystemElizabeth A Chrischilles, Joshua J Gagne, Bruce Fireman, et al.
JAMA Network Open|May 31, 2022
Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical TrialSean D Pokorney, Noelle Cocoros, Hussein R Al-Khalidi, et al.
Pageof 17

Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
Clinical Trials (London, England)|November 18, 2018
FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trialNoelle M Cocoros, Sean D Pokorney, Kevin Haynes, et al.
Journal of Clinical Epidemiology|October 1, 2020
PCORnet® 2020: current state, accomplishments, and future directionsChristopher B Forrest, Kathleen M McTigue, Adrian F Hernandez, et al.
Pharmacoepidemiology and Drug Safety|September 16, 2011
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systemsLisa J Herrinton, Jeffrey R Curtis, Lang Chen, et al.
The American Journal of Gastroenterology|December 12, 2022
Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's DiseaseMichael D Kappelman, Sruthi Adimadhyam, Laura Hou, et al.
Pharmacoepidemiology and Drug Safety|June 5, 2021
Validation of an ICD-10-based algorithm to identify stillbirth in the Sentinel SystemSusan E Andrade, Mayura Shinde, Tiffany A Moore Simas, et al.
BMJ Open Diabetes Research & Care|September 8, 2017
Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomesVincent Lo Re, Dena M Carbonari, M Elle Saine, et al.
JAMIA Open|November 29, 2023
Evaluating the impact of alternative phenotype definitions on incidence rates across a global data networkRupa Makadia, Azza Shoaibi, Gowtham A Rao, et al.
Pharmacoepidemiology and Drug Safety|July 6, 2012
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studiesVincent Lo Re, Kevin Haynes, Eileen E Ming, et al.
Pharmacoepidemiology and Drug Safety|January 11, 2018
Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel SystemElizabeth A Chrischilles, Joshua J Gagne, Bruce Fireman, et al.
JAMA Network Open|May 31, 2022
Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical TrialSean D Pokorney, Noelle Cocoros, Hussein R Al-Khalidi, et al.
Pageof 17